Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
Year: 2011
Type: article
Study design: Clinical Trial
Source: Investigational New Drugs
Authors: Jens Samol, Malcolm Ranson, Edwina Scott, Euan Macpherson, James Carmichael, Anne Thomas, James Cassidy
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: AstraZeneca
OpenAlex ID: W1994125700
